PFIZER INC
NYSE: PFE·New York, New York·CIK 0000078003
- Price
- $28.86
- Base IV
- $20.45
Valuation snapshot
At $28.86, the price sits between our base case ($20.45) and bull case ($36.19).
Values per share, from an .
- No growth
- …
- Loading earnings power
- Base case
- $20.45
- 71% of the price · range $6.01–$36.19
- Price vs base case
- 41% above
- $28.86 against $20.45
- Base case · our researched forecast, 2026-11-13See the research ↗
- Price vs base · derived: price − base caseWhat the price expects ↗
- Price · StockValuer price feed, 2026-11-16 closeno link today
Whisker on the base case runs bear $6.01 to bull $36.19. Values per share.
Price against each value
- Bear case
- $6.01
- Price 380% above
- No growth
- …
- —
- Base case
- $20.45
- Price 41% above
What does Pfizer do?
Pfizer develops and makes prescription medicines and vaccines that doctors use to prevent and treat diseases like cancer, COVID-19, heart disease, migraine, and bacterial and viral infections.
It brought in $63.6B of sales in the 12 months to Sep 2026.
Led by Albert Bourla, Chairman and Chief Executive Officer since 2019. Pfizer Inc. Form DEF 14A (2026 Proxy Statement)
- Industry
- Healthcare
- Based in
- New York, New York
- Trades on
- NYSE as PFE
Here is where each dollar a customer pays ends up. Out of every $1 of sales in the 12 months to Sep 2026, about 6¢ was left as profit after every cost, interest and tax. The biggest cost is everything else, including interest, 27¢ of every dollar.
- Making what it sells27¢
- Research and development18¢
- Sales, marketing and admin22¢
- Everything else, including interest27¢
- Left as profit6¢
Who pays Pfizer, and for what?
Pfizer discovers, makes and sells prescription medicines and vaccines in about 200 countries and territories. Most of its money comes from selling these products, such as the blood thinner Eliquis, the Prevnar pneumonia vaccines and cancer drugs. A small separate business makes drug ingredients and medicines for other companies under contract.
Pfizer mostly sells to drug wholesalers, and also directly to pharmacies, hospitals, clinics and government agencies such as the U.S. CDC. Insurers and government health programs decide a large part of what patients end up paying.
Primary Care
Medicines and vaccines that family doctors usually prescribe, including Eliquis, the Prevnar family, the Comirnaty COVID-19 vaccine, Abrysvo, the Paxlovid COVID-19 treatment and the migraine drug Nurtec.
COMIRNATY prefilled-syringe carton · September 2026Image: DailyMed, U.S. National Library of Medicine Specialty Care
Specialist medicines for immune conditions (Xeljanz, Enbrel outside the U.S. and Canada), rare diseases such as the Vyndaqel heart-disease family and hemophilia treatments, and some hospital anti-infectives.
VYNDAMAX 61 mg capsule carton · May 2026Image: DailyMed, U.S. National Library of Medicine Oncology
Cancer medicines including Ibrance, Xtandi, Padcev, Adcetris and Lorbrena, many of them added with the purchase of Seagen in 2023.
PADCEV 20 mg single-dose vial carton · August 2026Image: DailyMed, U.S. National Library of Medicine Pfizer CentreOne (PC1)
A contract manufacturing business that develops and makes medicines and specialty drug ingredients for other companies.
Eliquis (single largest product)
A blood thinner that prevents strokes and clots, developed and sold with Bristol Myers Squibb. It is counted inside Primary Care and was Pfizer's biggest single product in 2025.
Hospital and Biosimilars (new from 2026)
A new group created in January 2026 for older injectable hospital medicines and biosimilars, which are lower-cost versions of biologic drugs made by other companies. These products moved here from Specialty Care and Oncology, so 2025 figures for it are not shown separately.
INFLECTRA 100 mg single-dose vial carton · July 2026Image: DailyMed, U.S. National Library of Medicine
Where its work physically happens, beyond headquarters:
- Kalamazoo Manufacturing Site — Kalamazoo, United States. This 1,300-acre site is one of Pfizer's largest global facilities, producing active pharmaceutical ingredients via fermentation/bioprocessing and finished sterile injectable and oral drug products (including Paxlovid), making it critical to Pfizer's US manufacturing capacity.
- Puurs Manufacturing Plant — Puurs, Belgium. Pfizer's largest manufacturing and packaging site in Europe, producing over 400 million doses annually of injectable medicines and vaccines (including the BioNTech-partnered COVID-19 vaccine) distributed to more than 170 countries.
- Rocky Mount Manufacturing Site — Rocky Mount, United States. A 1.4 million square-foot plant on 250 acres producing sterile injectable anesthesia, analgesia, anti-infective, and neuromuscular blocker products that are frequently subject to hospital drug shortages, underscoring its importance to Pfizer's Hospital business.
- Sanford Manufacturing Site — Sanford, United States. A 230-acre flexible, multi-product manufacturing complex supporting sterile injectable and vaccine production for Pfizer's global supply chain.
- Groton Research and Development Site — Groton, United States. Pfizer's largest R&D campus, housing discovery and early-stage development laboratories central to the company's drug pipeline and future revenue-generating assets.
How is the business doing?
Sales grew from $41.7B in 2020 to $62.6B in 2025, about 8% a year.
After paying for its upkeep and new investment, it had $11.8B of cash to spare in the 12 months to Sep 2026.
What does management say it's aiming for?
Pfizer says it exists to deliver scientific breakthroughs that greatly improve the lives of patients, their families and their caregivers.
“Breakthroughs that change patients' lives”
Who is responsible for the plan?
Albert BourlaChairman and Chief Executive OfficerLeads Pfizer as Chief Executive Officer and chairs its Board of Directors. As CEO he is responsible for the whole company, which develops, makes and sells prescription medicines and vaccines.
- Aamir MalikExecutive Vice President, Chief U.S. Commercial Officer
Oversees Pfizer's U.S. commercial business, including its global marketing office and U.S. medical affairs, market access and policy functions. The Pfizer U.S. Commercial Division sells Pfizer's medicines and vaccines in the United States, and the 2026 proxy reports this division's revenue.
- Chris BoshoffChief Scientific Officer and President, Research & Development
Oversees R&D strategy and execution across all therapeutic areas, including discovery, clinical operations, regulatory, safety, pharmaceutical sciences and medical affairs. Pfizer's R&D organization discovers and develops the drug and vaccine candidates that the company may later bring to market and sell.
Roles checked November 13, 2026.
What management says it is working on now:
Get full value from recent deals
Pfizer's first 2026 priority is to get the most out of its big recent deals, such as buying Metsera (obesity drugs) in November 2025 and licensing drugs from YaoPharma and 3SBio.
Pfizer Inc. 2025 Form 10-KHit key research milestones
Management wants to deliver important results from drug trials, with research focused on cancer, internal medicine (including weight loss and migraine), vaccines and immune diseases.
Pfizer Inc. 2025 Form 10-KInvest for growth after 2028
Several best-selling drugs lose patent protection between 2026 and 2030, so Pfizer is putting money into new products to grow after 2028. About $500 million saved in research costs in 2025 is being put back into research programs in 2026.
Pfizer Inc. 2025 Form 10-KUse AI across the company
Pfizer plans to expand its use of AI and automation in research, manufacturing, sales and patient support, to work faster and lower costs.
Pfizer Inc. 2025 Form 10-KKeep cutting costs
Pfizer is running programs to bring its costs in line with the lower sales it expects in the long run and to make manufacturing cheaper. In August 2026 it announced another $2.5 billion in planned savings.
Pfizer Reports Second-Quarter 2026 Results (Form 8-K, Exhibit 99)
- Total revenue, full year 2026
- $60.5 billion to $62.5 billion
- Pfizer Reports Second-Quarter 2026 Results (Form 8-K, Exhibit 99)
- Adjusted diluted earnings per share, full year 2026
- $2.80 to $3.00
- Pfizer Reports Second-Quarter 2026 Results (Form 8-K, Exhibit 99)
- COVID-19 product revenue, full year 2026
- About $4 billion
- Pfizer Reports Second-Quarter 2026 Results (Form 8-K, Exhibit 99)
- Effective tax rate on adjusted income, full year 2026
- About 15%
- Pfizer Reports Second-Quarter 2026 Results (Form 8-K, Exhibit 99)
- Net savings from cost realignment program, by 2029
- About $5.7 billion by end of 2026; about $6.7 billion in total
- Pfizer Reports Second-Quarter 2026 Results (Form 8-K, Exhibit 99)
- Savings from manufacturing optimization program, by 2029
- About $3.0 billion in total
- Pfizer Reports Second-Quarter 2026 Results (Form 8-K, Exhibit 99)
What's changing right now?
Growth is holding steady. In Q3 2026 it sold 0% less than a year earlier. The year before, quarters averaged 0%.
The share price is about where it was in Sep 2026, near $28.86.
Recently
November 4, 2026
Expected annual revenue impact from exclusivity expiries (current year) changed to $1.1B
Pfizer Q3 2026 Form 10-QNovember 3, 2026
Effective tax rate on adjusted income, quarterly changed to 14.0%
Pfizer Q3 2026 earnings releaseNovember 3, 2026
Revenue growth excluding Comirnaty and Paxlovid, operational, quarterly YoY changed to 7.0%
Pfizer Q3 2026 earnings release
Coming up
Q4 2026
FDA decision on Talzenna plus Xtandi for prostate cancer
The FDA is reviewing this two-drug combination quickly (priority review) for a form of advanced prostate cancer, based on the TALAPRO-3 study.
Pfizer Reports Second-Quarter 2026 Results (Form 8-K, Exhibit 99)Through 2026
Large late-stage trial program for obesity drug berobenatide
Pfizer plans to move forward 10 late-stage (Phase 3) trials in 2026 of berobenatide, a once-monthly weight-loss injection from the Metsera purchase. These are part of more than 20 obesity trials.
Pfizer Reports Second-Quarter 2026 Results (Form 8-K, Exhibit 99)January 2027
Medicare-set prices start for Ibrance and Xtandi
Prices set by the government for Medicare patients take effect for two major cancer drugs, which could lower their U.S. revenue.
Pfizer Inc. 2025 Form 10-KNovember 2026 (patent); April 2028 (expected generic entry)
Eliquis main patent expires in the U.S.
The main U.S. patent on Eliquis ends in November 2026. Under court settlements, generic makers can launch on April 1, 2028, or earlier if Pfizer loses future patent challenges.
Pfizer Inc. 2025 Form 10-K
Our own estimate moved too: the base case went from $29.99 to $20.45 a share between our last two valuations.
What could go wrong?
No business is a sure thing. These are the risks we found, starting with the ones the company itself names. Where a risk would change part of the valuation, it says which.
Big drugs losing patent protection
Patents on several top sellers run out between 2026 and 2030, which lets cheaper copies come in. Pfizer expects a $1.5 billion revenue hit from this in 2026 and says the losses will speed up significantly over the next few years.
From the company's own filingsWould hit how fast sales growPfizer Inc. 2025 Form 10-K
Reliance on a few products
Twelve products made 65% of 2025 revenue, and Eliquis alone made 13%. Settled patent cases allow copies of Eliquis in the U.S. from April 2028, or sooner if Pfizer's remaining patents are struck down in court.
From the company's own filingsWould hit how fast sales growPfizer Inc. 2025 Form 10-K
Government limits on drug prices
A U.S. law (the Inflation Reduction Act) lets Medicare set prices for some drugs: Eliquis from 2026, Ibrance and Xtandi from 2027, Xeljanz from 2028. Pfizer also agreed with the U.S. government to lower some prices, and Medicare benefit changes cut 2025 revenue by about $1 billion.
From the company's own filingsWould hit how much of each sale it keepsPfizer Inc. 2025 Form 10-K
New drugs may fail or disappoint
Drugs in development can fail at any stage. Pfizer has made large bets on obesity (Metsera) and cancer (Seagen), both very crowded fields. In Q2 2026 it wrote down $4.3 billion in the value of drug assets, which caused a small reported loss for the quarter.
From the company's own filingsWould hit how much it has to reinvestPfizer Reports Second-Quarter 2026 Results (Form 8-K, Exhibit 99)
Shrinking COVID-19 sales
Sales of Comirnaty and Paxlovid have fallen sharply and depend on infection waves and changing vaccine advice. Pfizer cut its 2026 COVID revenue expectation from about $5 billion to about $4 billion.
From the company's own filingsWould hit how fast sales growPfizer Reports Second-Quarter 2026 Results (Form 8-K, Exhibit 99)
Tariffs, currencies and global events
41% of 2025 revenue came from outside the U.S., so exchange rates, trade disputes and conflicts can affect results. Pfizer's three-year break from U.S. drug tariffs depends on it investing more in U.S. manufacturing.
From the company's own filingsWould hit how much of each sale it keepsPfizer Inc. 2025 Form 10-K
The 10-Q cut the expected 2026 revenue hit from patent expiries to about $1.1B, which suggests erosion can come in slower than feared.
From our researchWould hit how fast sales growPfizer Q3 2026 Form 10-Q
Q3 2026 reported diluted EPS was $0.56 against $0.87 adjusted, showing large recurring charges (including a $650M acquired research charge for the Innovent deal).
From our researchWould hit how much of each sale it keepsPfizer Q3 2026 earnings release
Is it a good business?
From 2012 to 2025 it earned between 2% and 33% on its shareholders' equity, a median of 18%.
The number of shares has held roughly steady over the past year.
It owes $60.8B more than it holds in cash. An operating-profit comparison is unavailable from the published quarters.
What might it be worth?
The Valuation snapshot at the top of this page shows the answer. This is how we got there. A share is a slice of the business, so what a share is worth depends on what the business can earn for its owners from here on. We estimate that three ways, from cautious to hopeful, and call the result .
Today a share costs $28.86. Our put its value between $6.01 and $36.19, with $20.45 in the middle. Underneath sit two simpler checks: what it would cost to rebuild the business, its , and what today's profit is worth with no growth at all, its .
Bear case, $6.01
Pfizer's sales have hovered around $62-64 billion for three years, and this scenario assumes several of its biggest drugs lose patent protection faster than new medicines can replace them, so sales shrink for a few years and profits get thinner.
Base case, $20.45
Pfizer's sales have hovered around $62-64 billion since the COVID boom ended, and this scenario assumes they dip for a couple of years as major drugs lose patent protection, then return to modest growth as newer cancer and other medicines grow.
Bull case, $36.19
Pfizer's sales have hovered around $62-64 billion since the COVID boom ended, and this scenario assumes its newer cancer drugs and pipeline largely make up for the drugs losing patent protection, so sales dip only briefly before growing again and cost cuts lift profits.
Another way in: instead of asking what the business is worth, ask what today's price assumes it will do.
Why the gap?
The price expects more than we do.Price above value: 41%
For Pfizer to be worth today's $28.86, sales would need to grow about 4.2% a year. We assume they shrink 0.9%. Over the last 5 years, sales shrank 1.6% a year.
Or, if sales shrink 0.9% as we assume, the price works with a profit margin of 36.9% (we assume 29.0%).
Keep in mind: this is one way to read the price. Investors might be expecting other things, like higher profits or lower risk.
Do you think sales can grow 4.2% a year?
Try your own numbersWe're not very sure of this range: it scores 42 out of 100 on our checks. The weakest point is terminal-value dependency.
Test the assumptions
Our base value of $20.45 rests on three assumptions. Change any of them to see how the value per share responds.
- Revenue growth, 5-year average-0.9%
- Operating margin29.0%
- Long-term growth rate2.0%
This is an educational explanation built from public filings and our own research, not investment advice. It does not tell you whether to buy or sell anything.
Base estimate
$20.45 -29.2%


